BETA Beta Drugs Q4 FY26 results (Jan–Mar 2026) and concall
Beta Drugs Limited reported a robust Q4 FY26 with net revenue growing to INR396 crores and EBITDA margins expanding to 22.57%. Strong performance in branded sales and the Derma segment, which turned EBITDA positive, were key highlights. The company also completed the strategic acquisition of Nivian Lifesciences. However, export sales and CDMO growth were impacted by tender delays and supply issues with Platins, respectively.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q4 FY26: revenue up 1.1%, net profit up 283.5% against the same quarter last year.
| Line item | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 |
|---|---|---|---|---|---|---|
| Revenue | 48 | 54 | 66 | 54 | 50 +4% | 54 +1% |
| EBITDA | 6 | 5 | 8 | 5 | 7 +14% | 10 +86% |
| Net profit | 1 | 1 | 4 | 2 | 3 +333% | 5 +283% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
